Heart Failure. Congestive heart failure
Conditions
Interventions
Intervention 1: In the intervention group spironolactone tablets (tablets 25 mg pharmaceutical company Mino) at a dose of 12.5 mg daily after two weeks if there is no increase in creatinine and potass
Treatment - Drugs
In the intervention group spironolactone tablets (tablets 25 mg pharmaceutical company Mino) at a dose of 12.5 mg daily after two weeks if there is no increase in creatinine and potassium is increased
In the control group of spironolactone tablets that are quite similar to a placebo drug company is prepared
Sponsors
Vice chancellor for research of Iran university of medical sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients have a clear history of heart failure, according to Framingham criteria (the two major criteria or a major criteria and two minor criteria); Transthoracic Echocardiography with an Ejection Fraction(EF) more than or equal to 45%; and based on the criteria in the class New York Heart Association(NYHA) III and IV and have need to admition in Intesive Care Unit(ICU). Exclusion criteria: serum creatinine > 2.5 mgr/dlit in males and > 2 mgr/dlit in females or GFR 5.5 mEq/L.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NT-proBNP. Timepoint: At the time of admission, 72 hours of hospitalization, at discharge, one month and three months after discharge. Method of measurement: whole blood and FIA8000 Quantitative Immunoassay.;Transthorasic ECHO: LA size? grade(DD)? E/E'? E/A? PAP? RV size? MR(%)? decleration time? Tapse? EF. Timepoint: At the time of admission , one month and three months after discharge. Method of measurement: ECHO.;Heart functional class. Timepoint: At the time of admission, one month and three months after discharge. Method of measurement: NYHA.;Laboratory parameters. Timepoint: At the time of admission, 72 hours of hospitalization, at discharge, one month and three months after discharge. Method of measurement: Creat. Hb. Tn. Na. U.A. | — |
Secondary
| Measure | Time frame |
|---|---|
| The side effects of spironolactone. Timepoint: During treatment with spironolactone. Method of measurement: questionnaire.;APACHE II. Timepoint: In the first 24 hours of admission. Method of measurement: APACHE II score.;Length of stay in ICU. Timepoint: Length of stay in hospital. Method of measurement: The number of days of hospitalization in ICU. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Saeid Soltaniomid
Iran University of Medical Sciences
Outcome results
None listed